ORALHERP : treatment for labial herpes

Overview

ORALHERP is a filmogen liquid bandage specifically designed for the treatment of labial herpes lesions. This product targets pro-inflammatory proteins, contaminants, and impurities, providing a comprehensive approach to lesion treatment.

Mode of action

ORALHERP operates in three stages to aid in the healing of labial herpes lesions:

Protective Barrier Effect:

The product forms a protective barrier over the lesion, preventing the worsening of the lesion and the spread of the virus. 

Osmotic and Cleaning Effect:

ORALHERP aids in cleaning the lesion by removing impurities and contaminants, providing a clean environment for healing.

Cellular Repair and Growth Effect:

The product promotes the repair and growth of cells in the affected area, accelerating the healing process.

Clinical Trial

A randomized, double-blind, placebo-controlled clinical trial conducted over a period of 2 weeks with 60 patients showed significant results.

Key Findings

The main results of the study were as follows:

• The size of the lesion was significantly reduced within 7 days.
• The intensity of pain was significantly reduced within 21 days.
• Irritation was notably reduced within 14 days.
• Rectal bleeding was significantly reduced within 21 days.
• Lesion hydration improved within 14 days.
• Discomfort during defecation was reduced within 14 days.

See full publication (PDF)

MAIN RESULTS

Size of the lesion

• 55,3 % reduction in size of the lesion within 4 days.
• 87,4 % reduction in size of the lesion within 7 days.

Amount of virus

• 75 % reduction in amount of virus-infected cells within 4 days.
• 90 % reduction in amount of virus-infected cells within 7 days.
• Growth completely stopped between 7 and 14 days.

OTHER

• Clear improvement (on itching, burning and pain) was seen from day 4 onwards, and most patients had only minor topical irritation on day 7.
• Lesion tenderness, soreness, swelling around the lesion, and blister oozing which diminished progressively within a week and disappeared in most patients during the second week of treatment.